Our data suggest that the results are robust in different NSCLC datasets and the key target genes identified (ITGA2B, FLNA, GRB2, FCGR2A, and APP, etc.)seem to also be strongly expressed in the breast cancer and pancreatic cancer datasets we analyzed. This evidence concerns the gene FCGR2A and pancreatic neoplasm.